These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 12680707)

  • 1. Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione.
    Ferreira Cdos S; Martins PS; Demicheli C; Brochu C; Ouellette M; Frézard F
    Biometals; 2003 Sep; 16(3):441-6. PubMed ID: 12680707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate.
    Frézard F; Demicheli C; Ferreira CS; Costa MA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):913-6. PubMed ID: 11181379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione.
    Yan S; Li F; Ding K; Sun H
    J Biol Inorg Chem; 2003 Jul; 8(6):689-97. PubMed ID: 12827457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The thiol-based reduction of Bi(V) and Sb(V) anti-leishmanial complexes.
    Duffin RN; Stephens LJ; Blair VL; Kedzierski L; Andrews PC
    J Inorg Biochem; 2021 Aug; 221():111470. PubMed ID: 33971522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid reduction of pentavalent antimony by trypanothione: potential relevance to antimonial activation.
    Yan S; Wong IL; Chow LM; Sun H
    Chem Commun (Camb); 2003 Jan; (2):266-7. PubMed ID: 12585423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpectedly high levels of antimony (III) in the pentavalent antimonial drug Glucantime: insights from a new voltammetric approach.
    Salaün P; Frézard F
    Anal Bioanal Chem; 2013 Jun; 405(15):5201-14. PubMed ID: 23612869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathionylation of trypanosomal thiol redox proteins.
    Melchers J; Dirdjaja N; Ruppert T; Krauth-Siegel RL
    J Biol Chem; 2007 Mar; 282(12):8678-94. PubMed ID: 17242409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimony oxidation states in antileishmanial drugs.
    Franco MA; Barbosa AC; Rath S; Dorea JG
    Am J Trop Med Hyg; 1995 May; 52(5):435-7. PubMed ID: 7771610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Speciation of Sb(III) and Sb(V) in meglumine antimoniate pharmaceutical formulations by PSA using carbon nanotube electrode.
    Santos VS; Santos Wde J; Kubota LT; Tarley CR
    J Pharm Biomed Anal; 2009 Sep; 50(2):151-7. PubMed ID: 19423263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.
    Goyeneche-Patino DA; Valderrama L; Walker J; Saravia NG
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4503-6. PubMed ID: 18824610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiol-mediated NTA-Fe(III) reduction and lipid peroxidation.
    Spear N; Aust SD
    Arch Biochem Biophys; 1994 Jul; 312(1):198-202. PubMed ID: 8031128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
    Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate.
    Frézard F; Martins PS; Barbosa MC; Pimenta AM; Ferreira WA; de Melo JE; Mangrum JB; Demicheli C
    J Inorg Biochem; 2008 Apr; 102(4):656-65. PubMed ID: 18061680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the effect of antimony pressure on trypanothione reductase activity in Leishmania (Viannia) braziliensis.
    Zabala-Peñafiel A; Dias-Lopes G; Souza-Silva F; Miranda LFC; Conceição-Silva F; Alves CR
    Biochimie; 2023 May; 208():86-92. PubMed ID: 36586564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogen exchange equilibria in thiols.
    Hofstetter D; Thalmann B; Nauser T; Koppenol WH
    Chem Res Toxicol; 2012 Sep; 25(9):1862-7. PubMed ID: 22712484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimony(V) complex formation with adenine nucleosides in aqueous solution.
    Demicheli C; Frézard F; Lecouvey M; Garnier-Suillerot A
    Biochim Biophys Acta; 2002 Apr; 1570(3):192-8. PubMed ID: 12020809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.
    Wyllie S; Cunningham ML; Fairlamb AH
    J Biol Chem; 2004 Sep; 279(38):39925-32. PubMed ID: 15252045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of antimony tartrate with the tripeptide glutathione implication for its mode of action.
    Sun H; Yan SC; Cheng WS
    Eur J Biochem; 2000 Sep; 267(17):5450-7. PubMed ID: 10951203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH.
    dos Santos Ferreira C; de Castro Pimenta AM; Demicheli C; Frézard F
    Biometals; 2006 Oct; 19(5):573-81. PubMed ID: 16937264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.